I would have thought the share price might consolidate somewhere...

I would have thought the share price might consolidate somewhere around this level for a period, but who really knows. I am thinking the third PD1 site in Oz should be announced very soon. Next catalyst apart from the "Behind the Scenes" story (which I am not really expecting much in terms of market reaction) will likely be the PD1 dosing in late August, but I expect this time frame to be very tight. The potential and story of IMU is a remarkable one, which will make the patient shareholder very happy at the end of the day. I would expect around $10 to $12 M coming back into the balance sheet with November option exercise and R&D return this half financial year. This company is truly in a unique position, particularly when you consider the quality of their board, management and scientific team.